PARIS – Several prominent studies featured at the 2018 International Liver Congress (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), made clear that the industry has made progress but not yet found the silver bullet against one of its biggest foes: nonalcoholic steatohepatitis (NASH). If anything, ILC participants likely left Paris with more questions than answers about future directions for NASH study and treatment.